Switch of Osteogenesis in Vascular Calcification

血管钙化中成骨的转换

基本信息

批准号：
10197203
负责人：
Yucheng Yao
金额：
$ 39万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-07-01 至 2022-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10197203
关键词：
Affect American Aorta Arterial Fatty Streak Biological Assay Cells Complications of Diabetes Mellitus DNA sequencing Data Diabetes Mellitus Diabetic mouse Disease Endothelial Cells Endothelium Genes Genetic Transcription Glycogen Synthase Kinase 3 Human Investigation Knockout Mice Lead Mesenchymal Modeling Morbidity - disease rate Mus Osteoblasts Osteogenesis Patients Process Proteins Public Health Smad Proteins Source Technology Testing Therapeutic Tissue-Specific Gene Expression Tissues Vascular Diseases Vascular Endothelial Cell Vascular Endothelium Vascular calcification Work angiogenesis beta catenin calcification chromatin immunoprecipitation diabetic diabetic patient differential expression high risk high throughput screening high throughput technology improved inhibitor/antagonist knock-down matrix Gla protein mortality mouse model novel strategies novel therapeutic intervention osteogenic osteoprogenitor cell prevent small molecule transcriptome sequencing transdifferentiation treatment strategy

项目摘要

SUMMARY Therapeutic advances in vascular calcification may have far-reaching public benefits. Vascular calcification is a frequent complication of diabetes mellitus associated with the increase of morbidity and mortality. Although the precise mechanism has not been determined, vascular calcification is known to be an active process involving ectopic bone formation, in which osteogenic differentiation occurs in the cells transdifferentiated from other lineages. Previous studies have shown that vascular endothelial cells switch cell fate to differentiate into osteoblastic-like cells in vascular calcification. However, it is unknown if reversing this switch by inducing osteoblastic-endothelial transdifferentiation ameliorates vascular calcification. Advanced investigations have shown that the small molecules are able to reprogram and modulate cell fates, and also shown that endothelial-like cells can be transdifferentiated from other lineages. In present proposal, we take advantage of a small molecule identified by using high throughput technology, aiming to induce osteoblastic-endothelial transdifferentiation and investigate the effects on vascular calcification in diabetes mellitus. In preliminary data, we use a high throughput model to identify that GSK3 inhibitor SB216763 converts osteoblasts into endothelial-like cells. We show that SB216763 or limiting GSK3ß modulates protein levels of SMAD1 and ß- catenin and their transcriptional activity to switch the osteoblastic fate for endothelial differentiation. Furthermore, SB216763 treatment reduces EC-origin osteogenic differentiation and decreases calcification in aorta of matrix Gla protein null mouse, an established model of vascular calcification. The treatment of SB216763 also decreases arterial calcification in diabetic Ins2Akita/+ mice without affecting other tissues. Therefore, we hypothesize that GSK3 inhibition induces osteoblastic-endothelial transdifferentiation to ameliorate vascular calcification in diabetes mellitus. In specific Aim 1, we will elucidate the mechanism underlying osteoblastic-endothelial transdifferentiation induced by GSK3 inhibition. In specific Aim 2, we will determine if GSK3 inhibition ameliorates vascular calcification in diabetic mouse model. If successful, it will build osteoblastic-endothelial transdifferentiation as a new concept, and GSK3 inhibitor SB216763 may emerge as a new therapeutic approach to treat calcification in acquired vascular diseases.

概括血管钙化的治疗进展可能会产生深远的公共利益。糖尿病的常见并发症与发病率和死亡率的增加有关。确切的机制尚未确定，血管钙化已知是一个活跃的过程，涉及异位骨形成，其中从其他细胞转分化的细胞发生成骨分化先前的研究表明，血管内皮细胞可以改变细胞命运以分化为细胞。然而，尚不清楚是否可以通过诱导来逆转这种转变。高级研究表明，成骨细胞-内皮转分化可改善血管钙化。研究表明小分子能够重新编程和调节细胞命运，并且还表明在目前的提议中，我们利用了内皮样细胞可以从其他谱系转分化。使用高通量技术鉴定的小分子，旨在诱导成骨细胞内皮细胞转分化并研究对糖尿病血管钙化的影响在初步数据中，我们使用高通量模型来鉴定 GSK3 抑制剂 SB216763 将成骨细胞转化为我们发现 SB216763 或限制性 GSK3ß 调节 SMAD1 和 ß- 的蛋白水平。连环蛋白及其转录活性改变成骨细胞的命运以进行内皮分化。此外，SB216763 治疗可减少 EC 起源的成骨分化并减少钙化主动脉基质Gla蛋白缺失小鼠，已建立的血管钙化模型的治疗。 SB216763 还可减少糖尿病 Ins2Akita/+ 小鼠的动脉钙化，而不影响其他组织。因此，我们认为 GSK3 抑制会诱导成骨细胞-内皮细胞转分化改善糖尿病血管钙化在具体目标 1 中，我们将阐明其机制。 GSK3 抑制诱导潜在的成骨细胞内皮转分化。在具体目标 2 中，我们将确定 GSK3 抑制是否可以改善糖尿病小鼠模型中的血管钙化如果成功，将会改善。建立成骨细胞-内皮转分化新概念，GSK3抑制剂SB216763可能成为治疗获得性血管疾病钙化的新治疗方法。